Currently, genetic testing of KIT and PDGFRA is essential before treatment initiation (15), and comprehensive genomic profiling, such as for lung cancer, should be considered to identify driver mutations (e.g., SDH, BRAF, NF1, NTRK fusion, and FGFR fusion) for GISTs without KIT and PDGFRA mutations. This evidence concerns the gene KIT and lung cancer.